Live Breaking News & Updates on Department Of Immuno

Stay updated with breaking news from Department of immuno. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA approves Scopus BioPharma's IND application for CpG-STAT3siRNA.


The distinctive immuno-oncology RNA therapy targets multiple types of cancers.
Scopus BioPharma shares jumped 200% in the stock market on Monday morning.
Scopus BioPharma Inc. (NASDAQ: SCPS) said the U.S. Food and Drug Administration FDA approved its IND (investigational new drug) application on Monday for CpG-STAT3siRNA – its distinctive immuno-oncology RNA therapy that targets multiple types of cancers.
Impact on the share price
Following the announcement, Scopus BioPharma jumped roughly 200% in the stock market on Monday morning. The company touched a high of $15.42 per share (£10.90 per share) and is currently exchanging hands at $12.54 per share. In comparison, Scopus had started the year 2021 at a per-share price of $13.41. ....

United States , Marcin Kortylewski , Zhua Yu , Scopus Biopharma , Scopus Biopharma Inc , Drug Administration , Department Of Immuno , Nasdaq Stock Exchange , Hodgkin Lymphoma , Beckman Research Institute , ஒன்றுபட்டது மாநிலங்களில் , ஹுவா யூ , துறை ஆஃப் இம்யூனோ , நாஸ்டாக் ஸ்டாக் பரிமாற்றம் , ஹாட்ஜ்கின் லிம்போமா , பெக்மேன் ஆராய்ச்சி நிறுவனம் ,